nodes	percent_of_prediction	percent_of_DWPC	metapath
Indacaterol—ADRB2—prostate cancer	0.223	0.646	CbGaD
Indacaterol—CYP3A4—prostate cancer	0.122	0.354	CbGaD
Indacaterol—UGT1A1—Estradiol—prostate cancer	0.0569	0.133	CbGbCtD
Indacaterol—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0374	0.0875	CbGbCtD
Indacaterol—UGT1A1—Etoposide—prostate cancer	0.0372	0.0869	CbGbCtD
Indacaterol—ABCB1—Estramustine—prostate cancer	0.0305	0.0714	CbGbCtD
Indacaterol—ABCB1—Cabazitaxel—prostate cancer	0.0201	0.047	CbGbCtD
Indacaterol—CYP3A4—Bicalutamide—prostate cancer	0.0197	0.046	CbGbCtD
Indacaterol—ABCB1—Estrone—prostate cancer	0.0197	0.046	CbGbCtD
Indacaterol—CYP3A4—Estramustine—prostate cancer	0.0183	0.0428	CbGbCtD
Indacaterol—ABCB1—Ethinyl Estradiol—prostate cancer	0.0175	0.041	CbGbCtD
Indacaterol—CYP3A4—Abiraterone—prostate cancer	0.0163	0.0381	CbGbCtD
Indacaterol—CYP3A4—Flutamide—prostate cancer	0.0163	0.0381	CbGbCtD
Indacaterol—ABCB1—Conjugated Estrogens—prostate cancer	0.0129	0.0301	CbGbCtD
Indacaterol—CYP3A4—Cabazitaxel—prostate cancer	0.0121	0.0282	CbGbCtD
Indacaterol—CYP3A4—Estrone—prostate cancer	0.0118	0.0275	CbGbCtD
Indacaterol—ABCB1—Mitoxantrone—prostate cancer	0.0117	0.0273	CbGbCtD
Indacaterol—ABCB1—Estradiol—prostate cancer	0.0113	0.0264	CbGbCtD
Indacaterol—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0105	0.0246	CbGbCtD
Indacaterol—ABCB1—Prednisone—prostate cancer	0.00971	0.0227	CbGbCtD
Indacaterol—CYP3A4—Conjugated Estrogens—prostate cancer	0.00771	0.018	CbGbCtD
Indacaterol—ABCB1—Etoposide—prostate cancer	0.00737	0.0172	CbGbCtD
Indacaterol—CYP3A4—Mitoxantrone—prostate cancer	0.00701	0.0164	CbGbCtD
Indacaterol—CYP3A4—Estradiol—prostate cancer	0.00677	0.0158	CbGbCtD
Indacaterol—ABCB1—Docetaxel—prostate cancer	0.00675	0.0158	CbGbCtD
Indacaterol—CYP3A4—Prednisone—prostate cancer	0.00582	0.0136	CbGbCtD
Indacaterol—ABCB1—Doxorubicin—prostate cancer	0.00503	0.0118	CbGbCtD
Indacaterol—CYP3A4—Etoposide—prostate cancer	0.00442	0.0103	CbGbCtD
Indacaterol—CYP3A4—Docetaxel—prostate cancer	0.00404	0.00945	CbGbCtD
Indacaterol—UGT1A1—urine—prostate cancer	0.00365	0.375	CbGeAlD
Indacaterol—CYP3A4—Doxorubicin—prostate cancer	0.00301	0.00705	CbGbCtD
Indacaterol—Procaterol—ADRB2—prostate cancer	0.00278	1	CrCbGaD
Indacaterol—UGT1A1—prostate gland—prostate cancer	0.00131	0.134	CbGeAlD
Indacaterol—CYP3A4—urine—prostate cancer	0.00117	0.12	CbGeAlD
Indacaterol—UGT1A1—renal system—prostate cancer	0.000892	0.0917	CbGeAlD
Indacaterol—ADRB1—prostate gland—prostate cancer	0.000887	0.0911	CbGeAlD
Indacaterol—ABCB1—prostate gland—prostate cancer	0.000297	0.0305	CbGeAlD
Indacaterol—CYP3A4—renal system—prostate cancer	0.000286	0.0294	CbGeAlD
Indacaterol—ABCB1—seminal vesicle—prostate cancer	0.000251	0.0258	CbGeAlD
Indacaterol—ABCB1—epithelium—prostate cancer	0.000218	0.0224	CbGeAlD
Indacaterol—ABCB1—renal system—prostate cancer	0.000202	0.0208	CbGeAlD
Indacaterol—ABCB1—urethra—prostate cancer	0.000199	0.0204	CbGeAlD
Indacaterol—Nausea—Bicalutamide—prostate cancer	0.000162	0.00115	CcSEcCtD
Indacaterol—Cough—Estradiol—prostate cancer	0.000161	0.00114	CcSEcCtD
Indacaterol—Angina pectoris—Capecitabine—prostate cancer	0.00016	0.00114	CcSEcCtD
Indacaterol—Anaemia—Mitoxantrone—prostate cancer	0.000159	0.00113	CcSEcCtD
Indacaterol—Chest pain—Estradiol—prostate cancer	0.000157	0.00111	CcSEcCtD
Indacaterol—Myalgia—Estradiol—prostate cancer	0.000157	0.00111	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000156	0.0011	CcSEcCtD
Indacaterol—Hypokalaemia—Prednisone—prostate cancer	0.000155	0.0011	CcSEcCtD
Indacaterol—Dry mouth—Estradiol—prostate cancer	0.000153	0.00109	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Capecitabine—prostate cancer	0.000153	0.00109	CcSEcCtD
Indacaterol—ABCB1—bone marrow—prostate cancer	0.000153	0.0157	CbGeAlD
Indacaterol—Diabetes mellitus—Epirubicin—prostate cancer	0.000153	0.00108	CcSEcCtD
Indacaterol—Pneumonia—Docetaxel—prostate cancer	0.000153	0.00108	CcSEcCtD
Indacaterol—Dizziness—Ethinyl Estradiol—prostate cancer	0.000152	0.00108	CcSEcCtD
Indacaterol—Cardiac disorder—Etoposide—prostate cancer	0.000152	0.00108	CcSEcCtD
Indacaterol—Infestation NOS—Docetaxel—prostate cancer	0.000152	0.00108	CcSEcCtD
Indacaterol—Infestation—Docetaxel—prostate cancer	0.000152	0.00108	CcSEcCtD
Indacaterol—Cough—Mitoxantrone—prostate cancer	0.00015	0.00106	CcSEcCtD
Indacaterol—Infection—Estradiol—prostate cancer	0.000149	0.00106	CcSEcCtD
Indacaterol—Hyperglycaemia—Capecitabine—prostate cancer	0.000149	0.00105	CcSEcCtD
Indacaterol—Immune system disorder—Etoposide—prostate cancer	0.000148	0.00105	CcSEcCtD
Indacaterol—Pneumonia—Capecitabine—prostate cancer	0.000148	0.00105	CcSEcCtD
Indacaterol—Mediastinal disorder—Etoposide—prostate cancer	0.000148	0.00105	CcSEcCtD
Indacaterol—Nervous system disorder—Estradiol—prostate cancer	0.000147	0.00105	CcSEcCtD
Indacaterol—Infestation—Capecitabine—prostate cancer	0.000147	0.00104	CcSEcCtD
Indacaterol—Infestation NOS—Capecitabine—prostate cancer	0.000147	0.00104	CcSEcCtD
Indacaterol—Tachycardia—Estradiol—prostate cancer	0.000147	0.00104	CcSEcCtD
Indacaterol—Myalgia—Mitoxantrone—prostate cancer	0.000146	0.00104	CcSEcCtD
Indacaterol—Chest pain—Mitoxantrone—prostate cancer	0.000146	0.00104	CcSEcCtD
Indacaterol—Skin disorder—Estradiol—prostate cancer	0.000146	0.00104	CcSEcCtD
Indacaterol—Rash—Ethinyl Estradiol—prostate cancer	0.000145	0.00103	CcSEcCtD
Indacaterol—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000145	0.00103	CcSEcCtD
Indacaterol—Headache—Ethinyl Estradiol—prostate cancer	0.000144	0.00102	CcSEcCtD
Indacaterol—Diabetes mellitus—Doxorubicin—prostate cancer	0.000141	0.001	CcSEcCtD
Indacaterol—Hypersensitivity—Goserelin—prostate cancer	0.00014	0.000991	CcSEcCtD
Indacaterol—Infection—Mitoxantrone—prostate cancer	0.000139	0.000987	CcSEcCtD
Indacaterol—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000138	0.000981	CcSEcCtD
Indacaterol—Muscle spasms—Etoposide—prostate cancer	0.000137	0.000973	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000137	0.000971	CcSEcCtD
Indacaterol—Nausea—Ethinyl Estradiol—prostate cancer	0.000137	0.000971	CcSEcCtD
Indacaterol—Tachycardia—Mitoxantrone—prostate cancer	0.000137	0.00097	CcSEcCtD
Indacaterol—Skin disorder—Mitoxantrone—prostate cancer	0.000136	0.000965	CcSEcCtD
Indacaterol—Paraesthesia—Estradiol—prostate cancer	0.000135	0.000957	CcSEcCtD
Indacaterol—Oedema peripheral—Docetaxel—prostate cancer	0.000134	0.000952	CcSEcCtD
Indacaterol—Pruritus—Goserelin—prostate cancer	0.000134	0.000951	CcSEcCtD
Indacaterol—Dyspnoea—Estradiol—prostate cancer	0.000134	0.000951	CcSEcCtD
Indacaterol—Connective tissue disorder—Docetaxel—prostate cancer	0.000134	0.00095	CcSEcCtD
Indacaterol—Pruritus—Conjugated Estrogens—prostate cancer	0.000133	0.000942	CcSEcCtD
Indacaterol—Hyperglycaemia—Prednisone—prostate cancer	0.000132	0.000939	CcSEcCtD
Indacaterol—Anaemia—Etoposide—prostate cancer	0.000132	0.000936	CcSEcCtD
Indacaterol—ABCB1—testis—prostate cancer	0.000131	0.0134	CbGeAlD
Indacaterol—Oedema peripheral—Capecitabine—prostate cancer	0.00013	0.000922	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Estradiol—prostate cancer	0.00013	0.00092	CcSEcCtD
Indacaterol—Connective tissue disorder—Capecitabine—prostate cancer	0.00013	0.00092	CcSEcCtD
Indacaterol—Vertigo—Etoposide—prostate cancer	0.000128	0.00091	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000128	0.000905	CcSEcCtD
Indacaterol—Cardiac disorder—Docetaxel—prostate cancer	0.000126	0.000897	CcSEcCtD
Indacaterol—Paraesthesia—Mitoxantrone—prostate cancer	0.000126	0.000892	CcSEcCtD
Indacaterol—Dizziness—Goserelin—prostate cancer	0.000125	0.000889	CcSEcCtD
Indacaterol—Dyspnoea—Mitoxantrone—prostate cancer	0.000125	0.000886	CcSEcCtD
Indacaterol—Cough—Etoposide—prostate cancer	0.000125	0.000883	CcSEcCtD
Indacaterol—Dizziness—Conjugated Estrogens—prostate cancer	0.000124	0.000881	CcSEcCtD
Indacaterol—Immune system disorder—Docetaxel—prostate cancer	0.000123	0.000873	CcSEcCtD
Indacaterol—Mediastinal disorder—Docetaxel—prostate cancer	0.000123	0.000871	CcSEcCtD
Indacaterol—Cardiac disorder—Capecitabine—prostate cancer	0.000122	0.000869	CcSEcCtD
Indacaterol—Chest pain—Etoposide—prostate cancer	0.000121	0.000862	CcSEcCtD
Indacaterol—Hypokalaemia—Epirubicin—prostate cancer	0.000121	0.000858	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000121	0.000856	CcSEcCtD
Indacaterol—Rash—Goserelin—prostate cancer	0.000119	0.000848	CcSEcCtD
Indacaterol—Dermatitis—Goserelin—prostate cancer	0.000119	0.000847	CcSEcCtD
Indacaterol—Immune system disorder—Capecitabine—prostate cancer	0.000119	0.000845	CcSEcCtD
Indacaterol—Mediastinal disorder—Capecitabine—prostate cancer	0.000119	0.000843	CcSEcCtD
Indacaterol—Nasopharyngitis—Epirubicin—prostate cancer	0.000119	0.000843	CcSEcCtD
Indacaterol—Headache—Goserelin—prostate cancer	0.000119	0.000843	CcSEcCtD
Indacaterol—Malnutrition—Docetaxel—prostate cancer	0.000119	0.000841	CcSEcCtD
Indacaterol—Rash—Conjugated Estrogens—prostate cancer	0.000118	0.00084	CcSEcCtD
Indacaterol—Dermatitis—Conjugated Estrogens—prostate cancer	0.000118	0.000839	CcSEcCtD
Indacaterol—Headache—Conjugated Estrogens—prostate cancer	0.000118	0.000835	CcSEcCtD
Indacaterol—Infection—Etoposide—prostate cancer	0.000116	0.000821	CcSEcCtD
Indacaterol—Connective tissue disorder—Prednisone—prostate cancer	0.000115	0.000819	CcSEcCtD
Indacaterol—Malnutrition—Capecitabine—prostate cancer	0.000115	0.000815	CcSEcCtD
Indacaterol—Asthma—Epirubicin—prostate cancer	0.000115	0.000815	CcSEcCtD
Indacaterol—Muscle spasms—Docetaxel—prostate cancer	0.000114	0.000809	CcSEcCtD
Indacaterol—Tachycardia—Etoposide—prostate cancer	0.000114	0.000806	CcSEcCtD
Indacaterol—Skin disorder—Etoposide—prostate cancer	0.000113	0.000803	CcSEcCtD
Indacaterol—Nausea—Goserelin—prostate cancer	0.000113	0.000799	CcSEcCtD
Indacaterol—Hypokalaemia—Doxorubicin—prostate cancer	0.000112	0.000794	CcSEcCtD
Indacaterol—Angina pectoris—Epirubicin—prostate cancer	0.000112	0.000793	CcSEcCtD
Indacaterol—Nausea—Conjugated Estrogens—prostate cancer	0.000112	0.000791	CcSEcCtD
Indacaterol—Hypersensitivity—Estradiol—prostate cancer	0.000111	0.000785	CcSEcCtD
Indacaterol—Muscle spasms—Capecitabine—prostate cancer	0.00011	0.000783	CcSEcCtD
Indacaterol—Nasopharyngitis—Doxorubicin—prostate cancer	0.00011	0.00078	CcSEcCtD
Indacaterol—Anaemia—Docetaxel—prostate cancer	0.00011	0.000778	CcSEcCtD
Indacaterol—Tremor—Capecitabine—prostate cancer	0.000108	0.000763	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000107	0.000757	CcSEcCtD
Indacaterol—Pruritus—Estradiol—prostate cancer	0.000106	0.000754	CcSEcCtD
Indacaterol—Asthma—Doxorubicin—prostate cancer	0.000106	0.000754	CcSEcCtD
Indacaterol—Anaemia—Capecitabine—prostate cancer	0.000106	0.000753	CcSEcCtD
Indacaterol—Immune system disorder—Prednisone—prostate cancer	0.000106	0.000753	CcSEcCtD
Indacaterol—Palpitations—Docetaxel—prostate cancer	0.000105	0.000744	CcSEcCtD
Indacaterol—Paraesthesia—Etoposide—prostate cancer	0.000105	0.000742	CcSEcCtD
Indacaterol—Dyspnoea—Etoposide—prostate cancer	0.000104	0.000737	CcSEcCtD
Indacaterol—Hyperglycaemia—Epirubicin—prostate cancer	0.000104	0.000735	CcSEcCtD
Indacaterol—Cough—Docetaxel—prostate cancer	0.000103	0.000734	CcSEcCtD
Indacaterol—Angina pectoris—Doxorubicin—prostate cancer	0.000103	0.000734	CcSEcCtD
Indacaterol—Vertigo—Capecitabine—prostate cancer	0.000103	0.000732	CcSEcCtD
Indacaterol—Hypersensitivity—Mitoxantrone—prostate cancer	0.000103	0.000732	CcSEcCtD
Indacaterol—Pneumonia—Epirubicin—prostate cancer	0.000103	0.00073	CcSEcCtD
Indacaterol—Infestation NOS—Epirubicin—prostate cancer	0.000102	0.000726	CcSEcCtD
Indacaterol—Infestation—Epirubicin—prostate cancer	0.000102	0.000726	CcSEcCtD
Indacaterol—Malnutrition—Prednisone—prostate cancer	0.000102	0.000726	CcSEcCtD
Indacaterol—Palpitations—Capecitabine—prostate cancer	0.000101	0.00072	CcSEcCtD
Indacaterol—Chest pain—Docetaxel—prostate cancer	0.000101	0.000716	CcSEcCtD
Indacaterol—Myalgia—Docetaxel—prostate cancer	0.000101	0.000716	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Etoposide—prostate cancer	0.000101	0.000713	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.0001	0.000711	CcSEcCtD
Indacaterol—Cough—Capecitabine—prostate cancer	0.0001	0.000711	CcSEcCtD
Indacaterol—Dizziness—Estradiol—prostate cancer	9.94e-05	0.000705	CcSEcCtD
Indacaterol—Dry mouth—Docetaxel—prostate cancer	9.87e-05	0.000701	CcSEcCtD
Indacaterol—Upper respiratory tract infection—Doxorubicin—prostate cancer	9.87e-05	0.0007	CcSEcCtD
Indacaterol—Chest pain—Capecitabine—prostate cancer	9.77e-05	0.000694	CcSEcCtD
Indacaterol—Myalgia—Capecitabine—prostate cancer	9.77e-05	0.000694	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	9.71e-05	0.000689	CcSEcCtD
Indacaterol—Infection—Docetaxel—prostate cancer	9.61e-05	0.000682	CcSEcCtD
Indacaterol—Sinusitis—Epirubicin—prostate cancer	9.6e-05	0.000681	CcSEcCtD
Indacaterol—Hyperglycaemia—Doxorubicin—prostate cancer	9.58e-05	0.00068	CcSEcCtD
Indacaterol—Dry mouth—Capecitabine—prostate cancer	9.56e-05	0.000678	CcSEcCtD
Indacaterol—Pneumonia—Doxorubicin—prostate cancer	9.52e-05	0.000676	CcSEcCtD
Indacaterol—Nervous system disorder—Docetaxel—prostate cancer	9.49e-05	0.000673	CcSEcCtD
Indacaterol—ABCB1—lymph node—prostate cancer	9.48e-05	0.00974	CbGeAlD
Indacaterol—Rash—Estradiol—prostate cancer	9.47e-05	0.000672	CcSEcCtD
Indacaterol—Infestation NOS—Doxorubicin—prostate cancer	9.47e-05	0.000672	CcSEcCtD
Indacaterol—Infestation—Doxorubicin—prostate cancer	9.47e-05	0.000672	CcSEcCtD
Indacaterol—Dermatitis—Estradiol—prostate cancer	9.46e-05	0.000672	CcSEcCtD
Indacaterol—Anaemia—Prednisone—prostate cancer	9.45e-05	0.000671	CcSEcCtD
Indacaterol—Tachycardia—Docetaxel—prostate cancer	9.44e-05	0.00067	CcSEcCtD
Indacaterol—Headache—Estradiol—prostate cancer	9.41e-05	0.000668	CcSEcCtD
Indacaterol—Skin disorder—Docetaxel—prostate cancer	9.4e-05	0.000667	CcSEcCtD
Indacaterol—Infection—Capecitabine—prostate cancer	9.31e-05	0.000661	CcSEcCtD
Indacaterol—Nervous system disorder—Capecitabine—prostate cancer	9.19e-05	0.000652	CcSEcCtD
Indacaterol—Vertigo—Prednisone—prostate cancer	9.19e-05	0.000652	CcSEcCtD
Indacaterol—Tachycardia—Capecitabine—prostate cancer	9.14e-05	0.000649	CcSEcCtD
Indacaterol—Skin disorder—Capecitabine—prostate cancer	9.1e-05	0.000646	CcSEcCtD
Indacaterol—Oedema peripheral—Epirubicin—prostate cancer	9.05e-05	0.000642	CcSEcCtD
Indacaterol—Connective tissue disorder—Epirubicin—prostate cancer	9.03e-05	0.000641	CcSEcCtD
Indacaterol—Nausea—Estradiol—prostate cancer	8.92e-05	0.000633	CcSEcCtD
Indacaterol—Sinusitis—Doxorubicin—prostate cancer	8.88e-05	0.00063	CcSEcCtD
Indacaterol—Rash—Mitoxantrone—prostate cancer	8.83e-05	0.000626	CcSEcCtD
Indacaterol—Dermatitis—Mitoxantrone—prostate cancer	8.82e-05	0.000626	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.82e-05	0.000626	CcSEcCtD
Indacaterol—Headache—Mitoxantrone—prostate cancer	8.77e-05	0.000622	CcSEcCtD
Indacaterol—Myalgia—Prednisone—prostate cancer	8.71e-05	0.000618	CcSEcCtD
Indacaterol—Paraesthesia—Docetaxel—prostate cancer	8.69e-05	0.000617	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.65e-05	0.000614	CcSEcCtD
Indacaterol—Dyspnoea—Docetaxel—prostate cancer	8.63e-05	0.000612	CcSEcCtD
Indacaterol—Hypersensitivity—Etoposide—prostate cancer	8.58e-05	0.000609	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.54e-05	0.000606	CcSEcCtD
Indacaterol—Cardiac disorder—Epirubicin—prostate cancer	8.53e-05	0.000605	CcSEcCtD
Indacaterol—Paraesthesia—Capecitabine—prostate cancer	8.41e-05	0.000597	CcSEcCtD
Indacaterol—Oedema peripheral—Doxorubicin—prostate cancer	8.37e-05	0.000594	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Docetaxel—prostate cancer	8.35e-05	0.000593	CcSEcCtD
Indacaterol—Connective tissue disorder—Doxorubicin—prostate cancer	8.35e-05	0.000593	CcSEcCtD
Indacaterol—Dyspnoea—Capecitabine—prostate cancer	8.35e-05	0.000593	CcSEcCtD
Indacaterol—Nausea—Mitoxantrone—prostate cancer	8.32e-05	0.00059	CcSEcCtD
Indacaterol—Immune system disorder—Epirubicin—prostate cancer	8.3e-05	0.000589	CcSEcCtD
Indacaterol—Infection—Prednisone—prostate cancer	8.29e-05	0.000588	CcSEcCtD
Indacaterol—Mediastinal disorder—Epirubicin—prostate cancer	8.28e-05	0.000588	CcSEcCtD
Indacaterol—Pruritus—Etoposide—prostate cancer	8.24e-05	0.000585	CcSEcCtD
Indacaterol—Nervous system disorder—Prednisone—prostate cancer	8.18e-05	0.000581	CcSEcCtD
Indacaterol—Tachycardia—Prednisone—prostate cancer	8.15e-05	0.000578	CcSEcCtD
Indacaterol—Skin disorder—Prednisone—prostate cancer	8.11e-05	0.000575	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Capecitabine—prostate cancer	8.09e-05	0.000574	CcSEcCtD
Indacaterol—Malnutrition—Epirubicin—prostate cancer	8e-05	0.000568	CcSEcCtD
Indacaterol—Cardiac disorder—Doxorubicin—prostate cancer	7.89e-05	0.00056	CcSEcCtD
Indacaterol—Dizziness—Etoposide—prostate cancer	7.7e-05	0.000546	CcSEcCtD
Indacaterol—Muscle spasms—Epirubicin—prostate cancer	7.69e-05	0.000546	CcSEcCtD
Indacaterol—Immune system disorder—Doxorubicin—prostate cancer	7.68e-05	0.000545	CcSEcCtD
Indacaterol—Mediastinal disorder—Doxorubicin—prostate cancer	7.66e-05	0.000544	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Prednisone—prostate cancer	7.6e-05	0.00054	CcSEcCtD
Indacaterol—Paraesthesia—Prednisone—prostate cancer	7.49e-05	0.000532	CcSEcCtD
Indacaterol—Malnutrition—Doxorubicin—prostate cancer	7.4e-05	0.000525	CcSEcCtD
Indacaterol—Anaemia—Epirubicin—prostate cancer	7.39e-05	0.000525	CcSEcCtD
Indacaterol—Rash—Etoposide—prostate cancer	7.34e-05	0.000521	CcSEcCtD
Indacaterol—Dermatitis—Etoposide—prostate cancer	7.34e-05	0.000521	CcSEcCtD
Indacaterol—Headache—Etoposide—prostate cancer	7.29e-05	0.000518	CcSEcCtD
Indacaterol—Vertigo—Epirubicin—prostate cancer	7.19e-05	0.00051	CcSEcCtD
Indacaterol—Hypersensitivity—Docetaxel—prostate cancer	7.13e-05	0.000506	CcSEcCtD
Indacaterol—Muscle spasms—Doxorubicin—prostate cancer	7.11e-05	0.000505	CcSEcCtD
Indacaterol—Palpitations—Epirubicin—prostate cancer	7.07e-05	0.000502	CcSEcCtD
Indacaterol—Cough—Epirubicin—prostate cancer	6.98e-05	0.000495	CcSEcCtD
Indacaterol—Nausea—Etoposide—prostate cancer	6.92e-05	0.000491	CcSEcCtD
Indacaterol—Hypersensitivity—Capecitabine—prostate cancer	6.9e-05	0.00049	CcSEcCtD
Indacaterol—Pruritus—Docetaxel—prostate cancer	6.85e-05	0.000486	CcSEcCtD
Indacaterol—Anaemia—Doxorubicin—prostate cancer	6.84e-05	0.000485	CcSEcCtD
Indacaterol—Chest pain—Epirubicin—prostate cancer	6.81e-05	0.000483	CcSEcCtD
Indacaterol—Myalgia—Epirubicin—prostate cancer	6.81e-05	0.000483	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.76e-05	0.00048	CcSEcCtD
Indacaterol—Dry mouth—Epirubicin—prostate cancer	6.66e-05	0.000473	CcSEcCtD
Indacaterol—Vertigo—Doxorubicin—prostate cancer	6.65e-05	0.000472	CcSEcCtD
Indacaterol—Pruritus—Capecitabine—prostate cancer	6.63e-05	0.00047	CcSEcCtD
Indacaterol—Palpitations—Doxorubicin—prostate cancer	6.54e-05	0.000464	CcSEcCtD
Indacaterol—Infection—Epirubicin—prostate cancer	6.48e-05	0.00046	CcSEcCtD
Indacaterol—Cough—Doxorubicin—prostate cancer	6.46e-05	0.000458	CcSEcCtD
Indacaterol—Nervous system disorder—Epirubicin—prostate cancer	6.4e-05	0.000454	CcSEcCtD
Indacaterol—Dizziness—Docetaxel—prostate cancer	6.4e-05	0.000454	CcSEcCtD
Indacaterol—Tachycardia—Epirubicin—prostate cancer	6.37e-05	0.000452	CcSEcCtD
Indacaterol—Skin disorder—Epirubicin—prostate cancer	6.34e-05	0.00045	CcSEcCtD
Indacaterol—Chest pain—Doxorubicin—prostate cancer	6.3e-05	0.000447	CcSEcCtD
Indacaterol—Myalgia—Doxorubicin—prostate cancer	6.3e-05	0.000447	CcSEcCtD
Indacaterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.26e-05	0.000444	CcSEcCtD
Indacaterol—Dizziness—Capecitabine—prostate cancer	6.2e-05	0.00044	CcSEcCtD
Indacaterol—Dry mouth—Doxorubicin—prostate cancer	6.16e-05	0.000437	CcSEcCtD
Indacaterol—Hypersensitivity—Prednisone—prostate cancer	6.15e-05	0.000436	CcSEcCtD
Indacaterol—Rash—Docetaxel—prostate cancer	6.1e-05	0.000433	CcSEcCtD
Indacaterol—Dermatitis—Docetaxel—prostate cancer	6.1e-05	0.000433	CcSEcCtD
Indacaterol—Headache—Docetaxel—prostate cancer	6.06e-05	0.00043	CcSEcCtD
Indacaterol—Infection—Doxorubicin—prostate cancer	6e-05	0.000426	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.95e-05	0.000422	CcSEcCtD
Indacaterol—Nervous system disorder—Doxorubicin—prostate cancer	5.92e-05	0.00042	CcSEcCtD
Indacaterol—Rash—Capecitabine—prostate cancer	5.91e-05	0.000419	CcSEcCtD
Indacaterol—Pruritus—Prednisone—prostate cancer	5.9e-05	0.000419	CcSEcCtD
Indacaterol—Dermatitis—Capecitabine—prostate cancer	5.9e-05	0.000419	CcSEcCtD
Indacaterol—Tachycardia—Doxorubicin—prostate cancer	5.89e-05	0.000418	CcSEcCtD
Indacaterol—Headache—Capecitabine—prostate cancer	5.87e-05	0.000417	CcSEcCtD
Indacaterol—Skin disorder—Doxorubicin—prostate cancer	5.87e-05	0.000416	CcSEcCtD
Indacaterol—Paraesthesia—Epirubicin—prostate cancer	5.86e-05	0.000416	CcSEcCtD
Indacaterol—Dyspnoea—Epirubicin—prostate cancer	5.82e-05	0.000413	CcSEcCtD
Indacaterol—Nausea—Docetaxel—prostate cancer	5.75e-05	0.000408	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Epirubicin—prostate cancer	5.64e-05	0.0004	CcSEcCtD
Indacaterol—Nausea—Capecitabine—prostate cancer	5.57e-05	0.000395	CcSEcCtD
Indacaterol—Dizziness—Prednisone—prostate cancer	5.52e-05	0.000392	CcSEcCtD
Indacaterol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.5e-05	0.00039	CcSEcCtD
Indacaterol—Paraesthesia—Doxorubicin—prostate cancer	5.42e-05	0.000385	CcSEcCtD
Indacaterol—Dyspnoea—Doxorubicin—prostate cancer	5.38e-05	0.000382	CcSEcCtD
Indacaterol—Rash—Prednisone—prostate cancer	5.26e-05	0.000373	CcSEcCtD
Indacaterol—Dermatitis—Prednisone—prostate cancer	5.26e-05	0.000373	CcSEcCtD
Indacaterol—Headache—Prednisone—prostate cancer	5.23e-05	0.000371	CcSEcCtD
Indacaterol—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.21e-05	0.00037	CcSEcCtD
Indacaterol—Nausea—Prednisone—prostate cancer	4.96e-05	0.000352	CcSEcCtD
Indacaterol—Hypersensitivity—Epirubicin—prostate cancer	4.81e-05	0.000341	CcSEcCtD
Indacaterol—Pruritus—Epirubicin—prostate cancer	4.62e-05	0.000328	CcSEcCtD
Indacaterol—Hypersensitivity—Doxorubicin—prostate cancer	4.45e-05	0.000316	CcSEcCtD
Indacaterol—Dizziness—Epirubicin—prostate cancer	4.32e-05	0.000306	CcSEcCtD
Indacaterol—Pruritus—Doxorubicin—prostate cancer	4.27e-05	0.000303	CcSEcCtD
Indacaterol—Rash—Epirubicin—prostate cancer	4.12e-05	0.000292	CcSEcCtD
Indacaterol—Dermatitis—Epirubicin—prostate cancer	4.11e-05	0.000292	CcSEcCtD
Indacaterol—Headache—Epirubicin—prostate cancer	4.09e-05	0.00029	CcSEcCtD
Indacaterol—Dizziness—Doxorubicin—prostate cancer	3.99e-05	0.000283	CcSEcCtD
Indacaterol—Nausea—Epirubicin—prostate cancer	3.88e-05	0.000275	CcSEcCtD
Indacaterol—Rash—Doxorubicin—prostate cancer	3.81e-05	0.00027	CcSEcCtD
Indacaterol—Dermatitis—Doxorubicin—prostate cancer	3.8e-05	0.00027	CcSEcCtD
Indacaterol—Headache—Doxorubicin—prostate cancer	3.78e-05	0.000268	CcSEcCtD
Indacaterol—Nausea—Doxorubicin—prostate cancer	3.59e-05	0.000255	CcSEcCtD
Indacaterol—ADRB1—GPCR downstream signaling—CXCL8—prostate cancer	6.79e-06	9.18e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—JAK2—prostate cancer	6.76e-06	9.13e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PIK3CG—prostate cancer	6.71e-06	9.06e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—HPGDS—prostate cancer	6.71e-06	9.06e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IGF1R—prostate cancer	6.67e-06	9.02e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP2C19—prostate cancer	6.66e-06	9.01e-05	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—CXCL8—prostate cancer	6.64e-06	8.98e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—JAK2—prostate cancer	6.61e-06	8.94e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—LPL—prostate cancer	6.54e-06	8.84e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PHGDH—prostate cancer	6.54e-06	8.84e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—UMPS—prostate cancer	6.54e-06	8.84e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ARG2—prostate cancer	6.54e-06	8.84e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTT1—prostate cancer	6.5e-06	8.79e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—ACHE—prostate cancer	6.5e-06	8.79e-05	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—IL2—prostate cancer	6.49e-06	8.77e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PDGFRB—prostate cancer	6.48e-06	8.76e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP2A6—prostate cancer	6.43e-06	8.69e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—PIK3CB—prostate cancer	6.42e-06	8.68e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—LDHB—prostate cancer	6.41e-06	8.67e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—LPL—prostate cancer	6.4e-06	8.65e-05	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—IL2—prostate cancer	6.35e-06	8.58e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—INS—prostate cancer	6.35e-06	8.58e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PDGFRB—prostate cancer	6.34e-06	8.57e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ITGB3—prostate cancer	6.32e-06	8.54e-05	CbGpPWpGaD
Indacaterol—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	6.31e-06	8.53e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP3A5—prostate cancer	6.29e-06	8.51e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—PIK3CB—prostate cancer	6.28e-06	8.49e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—AKR1C3—prostate cancer	6.25e-06	8.45e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PRKACB—prostate cancer	6.22e-06	8.41e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—CREBBP—prostate cancer	6.22e-06	8.4e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	6.18e-06	8.35e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	6.17e-06	8.34e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP17A1—prostate cancer	6.16e-06	8.32e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	6.13e-06	8.28e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	6.12e-06	8.27e-05	CbGpPWpGaD
Indacaterol—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	6.09e-06	8.23e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PDHA1—prostate cancer	6.08e-06	8.22e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TCN2—prostate cancer	6.08e-06	8.22e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—UCP3—prostate cancer	6.08e-06	8.22e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTA3—prostate cancer	6.08e-06	8.22e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	6.03e-06	8.15e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	5.99e-06	8.1e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	5.98e-06	8.09e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PIK3CD—prostate cancer	5.89e-06	7.97e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—IL2—prostate cancer	5.89e-06	7.97e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TERT—prostate cancer	5.87e-06	7.94e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NCOA2—prostate cancer	5.87e-06	7.93e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.8e-06	7.84e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.8e-06	7.84e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—IL2—prostate cancer	5.77e-06	7.79e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TERT—prostate cancer	5.74e-06	7.77e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	5.62e-06	7.59e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—SLC5A5—prostate cancer	5.6e-06	7.56e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—NOS3—prostate cancer	5.57e-06	7.52e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTA4—prostate cancer	5.56e-06	7.51e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TBXAS1—prostate cancer	5.56e-06	7.51e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	5.49e-06	7.43e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—LEP—prostate cancer	5.48e-06	7.41e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP2E1—prostate cancer	5.47e-06	7.39e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CAV1—prostate cancer	5.43e-06	7.34e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTA2—prostate cancer	5.42e-06	7.32e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NQO1—prostate cancer	5.41e-06	7.31e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—KDR—prostate cancer	5.37e-06	7.26e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—LEP—prostate cancer	5.36e-06	7.25e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ABCG5—prostate cancer	5.35e-06	7.23e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SULT1A1—prostate cancer	5.35e-06	7.23e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—TH—prostate cancer	5.33e-06	7.2e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CAV1—prostate cancer	5.31e-06	7.18e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP3A4—prostate cancer	5.27e-06	7.12e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—KDR—prostate cancer	5.25e-06	7.1e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ESR1—prostate cancer	5.23e-06	7.08e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTA1—prostate cancer	5.23e-06	7.06e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP1B1—prostate cancer	5.18e-06	7e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTO1—prostate cancer	5.17e-06	6.99e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—HSD3B2—prostate cancer	5.17e-06	6.99e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NAT2—prostate cancer	5.17e-06	6.99e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PIK3CB—prostate cancer	5.14e-06	6.95e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ESR1—prostate cancer	5.12e-06	6.92e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—BAD—prostate cancer	5.11e-06	6.91e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PTGS2—prostate cancer	5.09e-06	6.88e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GGT1—prostate cancer	5.02e-06	6.78e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—BAD—prostate cancer	5e-06	6.76e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PLCB2—prostate cancer	4.95e-06	6.7e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—LRP2—prostate cancer	4.95e-06	6.7e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.95e-06	6.7e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—APC—prostate cancer	4.95e-06	6.69e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	4.95e-06	6.69e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NCOA1—prostate cancer	4.94e-06	6.68e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IRS1—prostate cancer	4.89e-06	6.61e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—EGF—prostate cancer	4.89e-06	6.61e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP19A1—prostate cancer	4.87e-06	6.59e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—P4HB—prostate cancer	4.86e-06	6.57e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—APC—prostate cancer	4.84e-06	6.54e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	4.84e-06	6.54e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IRS1—prostate cancer	4.78e-06	6.47e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—EGF—prostate cancer	4.78e-06	6.47e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	4.75e-06	6.42e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.73e-06	6.39e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—RXRA—prostate cancer	4.7e-06	6.36e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—INS—prostate cancer	4.68e-06	6.33e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	4.64e-06	6.28e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.61e-06	6.23e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	4.59e-06	6.2e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—INS—prostate cancer	4.58e-06	6.19e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—MED12—prostate cancer	4.53e-06	6.13e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IGF1—prostate cancer	4.53e-06	6.12e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—COMT—prostate cancer	4.53e-06	6.12e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTP1—prostate cancer	4.51e-06	6.09e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	4.51e-06	6.09e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GNG5—prostate cancer	4.5e-06	6.08e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	4.49e-06	6.07e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PTEN—prostate cancer	4.44e-06	6e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—ITPR1—prostate cancer	4.44e-06	6e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IGF1—prostate cancer	4.43e-06	5.99e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	4.41e-06	5.96e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	4.38e-06	5.92e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	4.35e-06	5.88e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NCOA3—prostate cancer	4.33e-06	5.85e-05	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	4.31e-06	5.82e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	4.3e-06	5.82e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	4.28e-06	5.79e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	4.26e-06	5.76e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	4.25e-06	5.75e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—EP300—prostate cancer	4.23e-06	5.72e-05	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	4.21e-06	5.7e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	4.21e-06	5.69e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—TYMS—prostate cancer	4.19e-06	5.67e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	4.17e-06	5.63e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—FGF2—prostate cancer	4.16e-06	5.63e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—GSTM1—prostate cancer	4.14e-06	5.6e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—HPGDS—prostate cancer	4.13e-06	5.58e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—NOS3—prostate cancer	4.11e-06	5.55e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.11e-06	5.55e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—FGF2—prostate cancer	4.07e-06	5.51e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—LPL—prostate cancer	4.07e-06	5.5e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—NOS3—prostate cancer	4.02e-06	5.43e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTT1—prostate cancer	4.01e-06	5.42e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ACHE—prostate cancer	4.01e-06	5.42e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—JAK2—prostate cancer	3.99e-06	5.4e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.96e-06	5.35e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CYP1A1—prostate cancer	3.93e-06	5.31e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	3.91e-06	5.29e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.9e-06	5.28e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MDM2—prostate cancer	3.9e-06	5.27e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—ERCC2—prostate cancer	3.9e-06	5.26e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.85e-06	5.21e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	3.84e-06	5.19e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PRKACB—prostate cancer	3.83e-06	5.18e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3.83e-06	5.17e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MDM2—prostate cancer	3.81e-06	5.15e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.79e-06	5.13e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	3.79e-06	5.12e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	3.76e-06	5.08e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	3.71e-06	5.01e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—MTHFR—prostate cancer	3.66e-06	4.95e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	3.64e-06	4.92e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NCOA2—prostate cancer	3.61e-06	4.89e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PPARA—prostate cancer	3.59e-06	4.86e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	3.56e-06	4.82e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	3.56e-06	4.81e-05	CbGpPWpGaD
Indacaterol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	3.52e-06	4.76e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CASP3—prostate cancer	3.49e-06	4.71e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IL2—prostate cancer	3.48e-06	4.71e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	3.48e-06	4.7e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—IL6—prostate cancer	3.46e-06	4.68e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.45e-06	4.66e-05	CbGpPWpGaD
Indacaterol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	3.44e-06	4.65e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CASP3—prostate cancer	3.41e-06	4.61e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IL2—prostate cancer	3.41e-06	4.6e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CCND1—prostate cancer	3.39e-06	4.59e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—IL6—prostate cancer	3.39e-06	4.58e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CAV1—prostate cancer	3.38e-06	4.56e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.37e-06	4.55e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	3.36e-06	4.54e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NQO1—prostate cancer	3.33e-06	4.5e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CCND1—prostate cancer	3.32e-06	4.49e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MMP9—prostate cancer	3.3e-06	4.45e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	3.29e-06	4.44e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	3.28e-06	4.44e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TH—prostate cancer	3.28e-06	4.44e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PTEN—prostate cancer	3.28e-06	4.43e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MMP9—prostate cancer	3.22e-06	4.36e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	3.21e-06	4.34e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PTEN—prostate cancer	3.2e-06	4.33e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	3.2e-06	4.32e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.19e-06	4.32e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—PIK3CA—prostate cancer	3.13e-06	4.23e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	3.13e-06	4.23e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—EP300—prostate cancer	3.12e-06	4.22e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GGT1—prostate cancer	3.09e-06	4.18e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PIK3CG—prostate cancer	3.08e-06	4.16e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—EP300—prostate cancer	3.06e-06	4.13e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NCOA1—prostate cancer	3.05e-06	4.12e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—SRC—prostate cancer	3.04e-06	4.11e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP19A1—prostate cancer	3e-06	4.06e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.97e-06	4.02e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.96e-06	4e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.93e-06	3.96e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—INS—prostate cancer	2.91e-06	3.94e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—RXRA—prostate cancer	2.9e-06	3.92e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.89e-06	3.91e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.87e-06	3.87e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—CREBBP—prostate cancer	2.85e-06	3.86e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—COMT—prostate cancer	2.79e-06	3.77e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTP1—prostate cancer	2.78e-06	3.75e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ITPR1—prostate cancer	2.73e-06	3.69e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—MYC—prostate cancer	2.72e-06	3.68e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.72e-06	3.67e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PIK3CD—prostate cancer	2.7e-06	3.66e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.66e-06	3.6e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.66e-06	3.6e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.66e-06	3.59e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.6e-06	3.52e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—TYMS—prostate cancer	2.58e-06	3.49e-05	CbGpPWpGaD
Indacaterol—UGT1A1—Metabolism—AKT1—prostate cancer	2.56e-06	3.46e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—NOS3—prostate cancer	2.55e-06	3.45e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—GSTM1—prostate cancer	2.55e-06	3.45e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.52e-06	3.4e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—LPL—prostate cancer	2.51e-06	3.39e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2.46e-06	3.33e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.42e-06	3.27e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—ERCC2—prostate cancer	2.4e-06	3.24e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PIK3CB—prostate cancer	2.36e-06	3.19e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PTGS2—prostate cancer	2.34e-06	3.16e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	2.31e-06	3.12e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	2.26e-06	3.06e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—MTHFR—prostate cancer	2.26e-06	3.05e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—TP53—prostate cancer	2.24e-06	3.02e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PPARA—prostate cancer	2.21e-06	2.99e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—TP53—prostate cancer	2.19e-06	2.96e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CAV1—prostate cancer	2.08e-06	2.81e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—IL6—prostate cancer	2.05e-06	2.77e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PTEN—prostate cancer	2.04e-06	2.75e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—IL6—prostate cancer	2e-06	2.71e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—EP300—prostate cancer	1.94e-06	2.63e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.9e-06	2.56e-05	CbGpPWpGaD
Indacaterol—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.89e-06	2.55e-05	CbGpPWpGaD
Indacaterol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.85e-06	2.5e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—INS—prostate cancer	1.79e-06	2.42e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—CREBBP—prostate cancer	1.76e-06	2.38e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.67e-06	2.25e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—NOS3—prostate cancer	1.57e-06	2.13e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.45e-06	1.96e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PTGS2—prostate cancer	1.44e-06	1.94e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—PIK3CA—prostate cancer	1.44e-06	1.94e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PTEN—prostate cancer	1.25e-06	1.7e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—EP300—prostate cancer	1.2e-06	1.62e-05	CbGpPWpGaD
Indacaterol—ABCB1—Metabolism—AKT1—prostate cancer	1.17e-06	1.59e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.85e-07	1.2e-05	CbGpPWpGaD
Indacaterol—CYP3A4—Metabolism—AKT1—prostate cancer	7.23e-07	9.78e-06	CbGpPWpGaD
